Details for New Drug Application (NDA): 218067
✉ Email this page to a colleague
NDA 218067 describes ERTAPENEM SODIUM, which is a drug marketed by Acs Dobfar Spa, Eugia Pharma, Gland Pharma Ltd, Qilu, Savior Lifetec Corp, and Sun Pharm, and is included in six NDAs. It is available from thirteen suppliers. Additional details are available on the ERTAPENEM SODIUM profile page.
The generic ingredient in ERTAPENEM SODIUM is ertapenem sodium. There are eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ertapenem sodium profile page.
The generic ingredient in ERTAPENEM SODIUM is ertapenem sodium. There are eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ertapenem sodium profile page.
Summary for 218067
| Tradename: | ERTAPENEM SODIUM |
| Applicant: | Qilu |
| Ingredient: | ertapenem sodium |
| Patents: | 0 |
Suppliers and Packaging for NDA: 218067
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ERTAPENEM SODIUM | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 218067 | ANDA | Qilu Pharmaceutical Co., Ltd. | 67184-0551 | 67184-0551-2 | 10 VIAL, SINGLE-DOSE in 1 CARTON (67184-0551-2) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE (67184-0551-1) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Oct 31, 2024 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
